The DOI matches its Crossref record; 287 of the 287 references it cites were found in a registry or an index.
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Open accessAbstract
Cystic fibrosis (CF) is a lethal inherited disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, which result in impairment of CFTR mRNA and protein expression, function, stability or a combination of these. Although CF leads to multifaceted clinical manifestations, the respiratory disorder represents the major cause of morbidity and mortality of these patients. The life expectancy of CF patients has substantially lengthened due to early diagnosis and improvements in symptomatic therapeutic regimens. Quality of life remains nevertheless limited, as these individuals are subjected to considerable clinical, psychosocial and economic burdens. Since the discovery of the CFTR gene in 1989, tremendous efforts have been made to develop therapies acting more upstream on the pathogenesis cascade, thereby overcoming the underlying dysfunctions caused by CFTR mutations. In this line, the advances in cell-based high-throughput screenings have been facilitating the fast-tracking of CFTR modulators. These modulator drugs have the ability to enhance or even restore the functional expression of specific CF-causing mutations, and they have been classified into five main groups depending on their effects on CFTR mutations: read-through agents, amplifiers, correctors, potentiators and stabilizers. To date, four CFTR modulators have reached the market, and these pharmaceutical therapies are transforming patients’ lives with short- and long-term improvements in clinical outcomes. Such breakthroughs have paved the way for the development of novel CFTR modulators, which are currently under experimental and clinical investigations. Recent insights into the CFTR structure will also be useful for the rational design of next-generation modulator drugs. This review aims to provide a summary of recent developments in CFTR-directed therapeutics. Barriers and future directions are also discussed in order to optimize treatment adherence, identify feasible and sustainable solutions for equitable access to these therapies, and continue to expand the pipeline of novel modulators that may result in effective precision medicine for all individuals with CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–287 of 287
Edgeworth, D. M., Keating, D., Ellis, M., Button, B., Williams, E., Clark, D., Tierney, A. C., Heritier, S. R., Kotsimbos, T. C., & Wilson, J. W. (2017) · Clinical Science · doi:10.1042/cs20170995 · Cited by 63
An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy
Duncan, G. A., Kim, N., Colon-Cortes, Y., Rodriguez, J., Mazur, M., Birket, S. E., Rowe, S. M., West, N. E., Livraghi-Butrico, A., Boucher, R. C., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.006 · Cited by 63
Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis
Berical, A. C., Lee, R. E., Randell, S. H., & Hawkins, F. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00074 · Cited by 63
Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains
Laselva, O., Molinski, S. V., Casavola, V., & Bear, C. E. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.111799 · Cited by 62
Bell, S. C., Barry, P. J., Boeck, K. D., Dřevínek, P., Elborn, J. S., Plant, B. J., Minic, P., Braeckel, E. V., Verhulst, S. L., Muller, K., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.04.014 · Cited by 61
Groot, K. M. D. W., Berkers, G., van der Wilt, R. E. P. M. –., van der Meer, R., Vonk, A. M., Dekkers, J. F., Geerdink, M., Heida-Michel, S., Kruisselbrink, E., Vries, R., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.10.022 · Cited by 61
Solem, C. T., Vera‐Llonch, M., Liu, S., Botteman, M. F., & Castiglione, B. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0465-z · Cited by 60
Ribosomal Stalk Protein Silencing Partially Corrects the ΔF508-CFTR Functional Expression Defect
Veit, G., Oliver, K. E., Apaja, P. M., Perdomo, D., Bidaud-Meynard, A., Lin, S.-T., Guo, J., Icyuz, M., Sorscher, E. J., Hartman, J. L., et al. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002462 · Cited by 59
Flume, P. A., Wainwright, C. E., Tullis, D. E., Rodriguez, S., Niknian, M., Higgins, M., Davies, J. C., & Wagener, J. S. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.06.002 · Cited by 59
Sermet‐Gaudelus, I., Delion, M. F., Durieu, I., Jacquot, J. P., & Hubert, D. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2016.09.003 · Cited by 57
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
Sermet‐Gaudelus, I., Clancy, J. P., Nichols, D. P., Nick, J. A., Boeck, K. D., Solomon, G. M., Mall, M. A., Bolognese, J. A., Bouisset, F., den Hollander, W., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.10.015 · Cited by 57
Tomati, V., Sondo, E., Armirotti, A., Caci, E., Pesce, E., Marini, M., Gianotti, A., Jeon, Y. J., Cilli, M., Pistorio, A., et al. (2015) · Scientific Reports · doi:10.1038/srep12138 · Cited by 55
Leonard, A., Lebecque, P., Dingemanse, J., & Leal, T. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.12.004 · Cited by 54
Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons
Pranke, I. M., Bidou, L., Martin, N., Blanchet, S., Hatton, A., Karri, S., Cornu, D., Costes, B., Chevalier, B., Tondelier, D., et al. (2018) · ERJ Open Research · doi:10.1183/23120541.00080-2017 · Cited by 54
Decreased mRNA and protein stability of W1282X limits response to modulator therapy
Aksit, M. A., Bowling, A. D., Evans, T. A., Joynt, A. T., Osorio, D. L., Patel, S. U., West, N. E., Merlo, C. A., Sosnay, P. R., Cutting, G. R., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.02.009 · Cited by 54
Precision Medicine: At What Price?
Ferkol, T. W., & Quinton, P. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1428ed · Cited by 53
Noël, S., Wilke, M., Bot, A. G. M., de Jonge, H. R., & Becq, F. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.135582 · Cited by 53
High affinity ATP/ADP analogues as new tools for studying CFTR gating
Zhou, Z., Wang, X., Li, M., Sohma, Y., Zou, X., & Hwang, T. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2005.095083 · Cited by 53
Mutyam, V., Libby, E. F., Peng, N., Hadjiliadis, D., Bonk, M. P., Solomon, G. M., & Rowe, S. M. (2016) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2016.09.005 · Cited by 53
Sabirzhanova, I. B., Lopes‐Pacheco, M., Rapino, D., Grover, R., Handa, J. T., Guggino, W. B., & Cebotaru, L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.647685 · Cited by 52
Self-citationLoo, T. W., & Clarke, D. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.020 · Cited by 52
Bomberger, J. M., Coutermarsh, B., Barnaby, R., & Stanton, B. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.338855 · Cited by 51
Cryo-EM Visualization of an Active High Open Probability CFTR Anion Channel
Fay, J. F., Aleksandrov, L. A., Jensen, T. J., Cui, L., Kousouros, J. N., He, L., Aleksandrov, A. A., Gingerich, D. S., Riordan, J. R., & Chen, J. Z. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00763 · Cited by 51
Schneider‐Futschik, E. K. (2018) · Drug Metabolism Letters · doi:10.2174/1872312812666180328105259 · Cited by 51
Might Brushed Nasal Cells Be a Surrogate for CFTR Modulator Clinical Response?
Pranke, I., Hatton, A., Masson, A., Flament, T., Le Bourgeois, M., Chedevergne, F., Bailly, C., Urbach, V., Hinzpeter, A., Edelman, A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201808-1436le · Cited by 50
Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking
Carlile, G. W., Robert, R., Goepp, J., Matthes, E., Liao, J., Kus, B., MacKnight, S. D., Rotin, D., Hanrahan, J. W., & Thomas, D. Y. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.06.001 · Cited by 50
A five-year retrospective analysis of adherence in cystic fibrosis
Shakkottai, A., Kidwell, K., Townsend, M., & Nasr, S. Z. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23307 · Cited by 50
Slowing ribosome velocity restores folding and function of mutant CFTR
Oliver, K. E., Rauscher, R., Mijnders, M., Wang, W., Wolpert, M. J., Maya, J., Sabusap, C. M. P., Kesterson, R. A., Kirk, K. L., Rab, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124282 · Cited by 50
Rapino, D., Sabirzhanova, I. B., Lopes‐Pacheco, M., Grover, R., Guggino, W. B., & Cebotaru, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119796 · Cited by 49
Self-citationAdam, R. J., Hisert, K. B., Dodd, J. D., Grogan, B., Launspach, J. L., Fedler, J. K., Gallagher, C. G., Sieren, J., Gross, T. J., Fischer, A. J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86183 · Cited by 49
Quittner, A. L., Suthoff, E. D., Rendas‐Baum, R., Bayliss, M. S., Sermet‐Gaudelus, I., Castiglione, B., & Vera‐Llonch, M. (2015) · Health and Quality of Life Outcomes · doi:10.1186/s12955-015-0293-6 · Cited by 48
Overcoming barriers to a successful transition from pediatric to adult care
Goralski, J. L., Nasr, S. Z., & Uluer, A. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23778 · Cited by 48
McColley, S. A., Konstan, M. W., Ramsey, B. W., Elborn, J. S., Boyle, M., Wainwright, C. E., Waltz, D. A., Vera‐Llonch, M., Marigowda, G., Jiang, J. G., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.07.011 · Cited by 48
Merkert, S., Schubert, M., Olmer, R., Engels, L., Radetzki, S., Veltman, M., Scholte, B. J., Zöllner, J., Pedemonte, N., Galietta, L. J. V., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.04.014 · Cited by 48
Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27
Lopes‐Pacheco, M., Boinot, C., Sabirzhanova, I. B., Morales, M. M., Guggino, W. B., & Cebotaru, L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.671925 · Cited by 47
Self-citationRuffin, M., Roussel, L., Maillé, É., Rousseau, S., & Brochiero, E. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00198.2017 · Cited by 47
Balázs, A., & Mall, M. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01112 · Cited by 47
Identification and Characterization of Novel CFTR Potentiators
Gees, M., Musch, S., der Plas, S. E. V., Wesse, A.-S., Vandevelde, A., Verdonck, K., Mammoliti, O., Hwang, T., Sonck, K., Stouten, P. F. W., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01221 · Cited by 47
Cell Therapy for Cystic Fibrosis Lung Disease: Regenerative Basal Cell Amplification
Hayes, D., Kopp, B. T., Hill, C. L., Lallier, S. W., Schwartz, C. M., Tadesse, M., Alsudayri, A., & Reynolds, S. D. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0098 · Cited by 47
Potentiators of Defective ΔF508–CFTR Gating that Do Not Interfere with Corrector Action
Phuan, P., Veit, G., Tan, J. A., Finkbeiner, W. E., Lukács, G. L., & Verkman, A. S. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099689 · Cited by 46
Gene Therapy for Cystic Fibrosis Lung Disease: Overcoming the Barriers to Translation to the Clinic
Donnelley, M., & Parsons, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01381 · Cited by 46
Mutation-specific dual potentiators maximize rescue of CFTR gating mutants
Veit, G., Fonte, D. F. D., Avramescu, R. G., Premchandar, A., Bagdány, M., Xu, H., Bensinger, D., Stubba, D., Schmidt, B., Matouk, E., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.10.011 · Cited by 46
Lucarelli, M., Narzi, L., Pierandrei, S., et al. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181ead634 · Cited by 45
Augmentation of CFTR maturation byS-nitrosoglutathione reductase
Zaman, K., Sawczak, V., Zaidi, A., Butler, M., Bennett, D., Getsy, P. M., Zeinomar, M., Greenberg, Z., Forbes, M., Rehman, S., et al. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00269.2014 · Cited by 44
Lopes‐Pacheco, M., Boinot, C., Sabirzhanova, I. B., Rapino, D., & Cebotaru, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000475578 · Cited by 43
Self-citationMutation-specific downregulation of CFTR2 variants by gating potentiators
Avramescu, R. G., Kai, Y., Xu, H., Bidaud-Meynard, A., Schnúr, A., Frenkiel, S., Matouk, E., Veit, G., & Lukacs, G. L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx367 · Cited by 43
Pluripotent Stem Cell Platforms for Drug Discovery
Chen, K. G., Mallon, B. S., Park, K., Robey, P. G., McKay, R. D. G., Gottesman, M. M., & Zheng, W. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.009 · Cited by 43
Amaral, M. D., Boeck, K. D., Amaral, M. D., Davies, J. C., Boeck, K. D., Dřevínek, P., Elborn, J. S., Kerem, E., & Lee, T. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.06.010 · Cited by 43
Strauss, D. G., & Blinova, K. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.009 · Cited by 42
High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations
Liang, F., Shang, H., Jordan, N. J., Wong, E., Mercadante, D. L., Saltz, J., Mahiou, J., Bihler, H. J., & Mense, M. (2017) · SLAS TECHNOLOGY · doi:10.1177/2472630317692561 · Cited by 42
Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer
Fukuda, R., & Okiyoneda, T. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01100 · Cited by 42
Wilde, G. D., Gees, M., Musch, S., Verdonck, K., Jans, M., Wesse, A.-S., Singh, A. K., Hwang, T., Christophe, T., Pizzonero, M., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00514 · Cited by 41
Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis
Scanio, M. J. C., Searle, X. B., Liu, B., Koenig, J. R., Altenbach, R. J., Gfesser, G. A., Bogdan, A. R., Greszler, S. N., Zhao, G., Singh, A. K., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00377 · Cited by 39
R560S: A class II CFTR mutation that is not rescued by current modulators
Awatade, N. T., Ramalho, S. S., Silva, I. A. L., Felício, V., Botelho, H. M., de Poel, E., Vonk, A. M., Beekman, J. M., Farinha, C. M., & Amaral, M. D. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.07.001 · Cited by 37
Davies, J. C., de Steen, O. V., Koningsbruggen-Rietschel, S. V., Dřevínek, P., Derichs, N., McKone, E. F., Kanters, D., Allamassey, L., Namour, F., de Kock, H., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.006 · Cited by 37
Cui, G., Stauffer, B. B., Imhoff, B. R., Rab, A., Hong, J. S., Sorscher, E. J., & McCarty, N. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-49921-4 · Cited by 37
Correctors Rescue CFTR Mutations in Nucleotide‐Binding Domain 1 (NBD1) by Modulating Proteostasis
Lopes‐Pacheco, M., Sabirzhanova, I. B., Rapino, D., Morales, M. M., Guggino, W. B., & Cebotaru, L. (2016) · ChemBioChem · doi:10.1002/cbic.201500620 · Cited by 36
Self-citationFlume, P. A., Suthoff, E. D., Kosinski, M. R., Marigowda, G., & Quittner, A. L. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.12.004 · Cited by 36
Tomati, V., Pesce, E., Caci, E., Sondo, E., Scudieri, P., Marini, M., Amato, F., Castaldo, G., Ravazzolo, R., Galietta, L. J. V., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816595 · Cited by 35
A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease
Hutt, D. M., Loguercio, S., Campos, A. R., & Balch, W. E. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.017 · Cited by 35
SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis
Corvol, H., Mésinèle, J., Douksieh, I.-H., Strug, L. J., Boëlle, P., & Guillot, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00828 · Cited by 35
Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor
Garg, V., Shen, J., Li, C., Agarwal, S., Gebre, A., Robertson, S. M. C., Huang, J., Han, L., Jiang, L., Stephan, K., et al. (2019) · Clinical and Translational Science · doi:10.1111/cts.12610 · Cited by 35
Singh, A. K., Fan, Y., Balut, C., Alani, S., Manelli, A. M., Swensen, A. M., Jia, Y., Neelands, T. R., Vortherms, T. A., Liu, B., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261800 · Cited by 32
Alshafie, W., Chappe, F. G., Li, M., Anini, Y., & Chappe, V. M. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00296.2013 · Cited by 31
Byrnes, L. J., Xu, Y., Qiu, X., Hall, J. D., & West, G. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-22959-6 · Cited by 30
Clarke, L. A., Awatade, N. T., Felício, V., Silva, I. A. L., Calucho, M., Pereira, L., Azevedo, P., Cavaco, J., Barreto, C., Bertuzzo, C. S., et al. (2018) · Human Mutation · doi:10.1002/humu.23692 · Cited by 30
Beumer, W., Swildens, J., Leal, T., Noël, S., Anthonijsz, H. J. A., van der Horst, G., Kuiperij-Boersma, H., Potman, M., van Putten, C., Biasutto, P., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219182 · Cited by 30
Matos, A. M., Gomes‐Duarte, A., Faria, M., Barros, P., Jordan, P., Amaral, M. D., & Matos, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-31514-2 · Cited by 29
Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia
Tomati, V., Caci, E., Ferrera, L., Pesce, E., Sondo, E., Cholon, D. M., Quinney, N. L., Boyles, S. E., Armirotti, A., Ravazzolo, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98699 · Cited by 27
Liu, Q., Sabirzhanova, I. B., Bergbower, E. A. S., Yanda, M. K., Guggino, W. G., & Cebotaru, L. (2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000146 · Cited by 25
Koningsbruggen-Rietschel, S. V., Conrath, K., Fischer, R., Sutharsan, S., Kempa, A. T., Gleiber, W., Schwarz, C., Hector, A., Osselaer, N. V., Pano, A., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.09.006 · Cited by 22
Sharma, D., Xing, S., Hung, Y.-T., Caskey, R. N., Dowell, M. L., & Touchette, D. R. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0914-3 · Cited by 20
Berg, A. P., Hallowell, S., Tibbetts, M., Beasley, C., Brown-Phillips, T., Healy, A., Pustilnik, L. R., Doyonnas, R., & Pregel, M. J. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219849375 · Cited by 20
Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery
Davies, J. C., Dřevínek, P., Elborn, J. S., Kerem, E., Lee, T., Amaral, M. D., Boeck, K. D., Davies, J. C., Dřevínek, P., Elborn, J. S., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.06.011 · Cited by 20
Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis
Suthoff, E. D., Bonafede, M., Limone, B. L., O’Callaghan, L., Sawicki, G. S., & Wagener, J. S. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1178125 · Cited by 18
Cystic fibrosis drug is not cost effective, says NICE
Gulland, A. (2016) · BMJ · doi:10.1136/bmj.i3409 · Cited by 18
Increases in cytosolic Ca2+ induce dynamin- and calcineurin-dependent internalisation of CFTR
Patel, W., Moore, P. J., Sassano, M. F., Lopes‐Pacheco, M., Aleksandrov, A. A., Amaral, M. D., Tarran, R., & Gray, M. A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2989-3 · Cited by 18
Self-citationCK19 stabilizes CFTR at the cell surface by limiting its endocytic pathway degradation
Hou, X., Wu, Q., Rajagopalan, C., Zhang, C., Bouhamdan, M., Wei, H., Chen, X., Zaman, K., Li, C., Sun, X., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201901050r · Cited by 18
Higher Risk of Acute Cellular Rejection in Lung Transplant Recipients with Cystic Fibrosis
Calabrese, F., Lunardi, F., Nannini, N., Balestro, E., Loy, M., Marulli, G., Calabrese, F. A., Vuljan, S. E., Schiavon, M., Perissinotto, E., et al. (2015) · Annals of Transplantation · doi:10.12659/aot.894785 · Cited by 17
Variable Responses to CFTR Correctors in vitro: Estimating the Design Effect in Precision Medicine
Matthes, E., Goepp, J., Martini, C., Shan, J., Liao, J., Thomas, D. Y., & Hanrahan, J. W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01490 · Cited by 17
Brinks, V., Lipinska, K., de Jager, M., Beumer, W., Button, B. M., Livraghi-Butrico, A., Henig, N. R., & Matthee, B. (2019) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2018.1502 · Cited by 16
Diana, A., Polizzi, A. M., Santostasi, T., et al. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2016.15 · Cited by 13
Lopes‐Pacheco, M., Kitoko, J. Z., Morales, M. M., Petrs‐Silva, H., & Rocco, P. R. M. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.09.015 · Cited by 11
Self-citationPotentiation of ΔF508- and G551D-CFTR-Mediated Cl- Current by Novel Hydroxypyrazolines
Park, J., Khloya, P., Seo, Y., Kumar, S., Lee, H. K., Jeon, D.-K., Jo, S., Sharma, P. K., & Namkung, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149131 · Cited by 10
Michels, M., Matte, Ú. D. S., Fraga, L. R., Mancuso, A. C. B., Ligabue‐Braun, R., Berneira, E. F. R., Siebert, M., & Sanseverino, M. T. V. (2019) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2018-0148 · Cited by 9
Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity
Armirotti, A., Tomati, V., Matthes, E., Veit, G., Cholon, D. M., Phuan, P., Braccia, C., Guidone, D., Gentzsch, M., Lukács, G. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46639-1 · Cited by 9
Editorial: Emerging Therapeutic Approaches for Cystic Fibrosis
Lopes‐Pacheco, M., Pedemonte, N., & Kicic, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01440 · Cited by 6
Self-citation
Cited by
ECFS best practice guidelines: the 2018 revision
Castellani, C., Duff, A. J. A., Bell, S. C., Heijerman, H. G. M., Munck, A., Ratjen, F., Sermet-Gaudelus, I., Southern, K. W., Barben, J., Flume, P. A., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.006 · Cited by 765
Physiology and pathophysiology of human airway mucus
Hill, D. B., Button, B., Rubinstein, M., & Boucher, R. C. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2021 · Cited by 366
Deubiquitinase-targeting chimeras for targeted protein stabilization
Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00971-2 · Cited by 344
Scotet, V., L’Hostis, C., & Férec, C. (2020) · Genes · doi:10.3390/genes11060589 · Cited by 317
Zemanick, E. T., Taylor-Cousar, J. L., Davies, J., Gibson, R. L., Mall, M. A., McKone, E. F., McNally, P., Ramsey, B. W., Rayment, J. H., Rowe, S. M., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202102-0509oc · Cited by 305
Metadata
- Authors
- Lopes-Pacheco, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-02-21
- Volume
- 10
- Pages
- 1662-1662
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3008025512
- Cited by
- 535
- References
- 287
- FWCI
- 37.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.